Patent pending
Bacterial wound infection affects over 100 million people worldwide including:
  • 50 million diabetics with chronic wounds
  • 11 million patients with burns
  • 5 million patients with surgical wounds

Existing wound infection treatments mainly rely on antibiotics that are inefficient towards drug-resistant bacteria and silver-based wound dressings that often cause skin irritation, delay wound healing, and inactivate bacteria only partially, leading to reoccurring infections and amputations.

Bacterial wound infections cause 10 million amputations every year.


Nanordica Medical has invented and patented a nanoformula enabling to develop 5x more efficient antibacterial products compared to the existing market alternatives.

Nanordica nanoformula has proven antibacterial efficiency confirmed by the North Estonia Medical Centre. Nanoformula can be used to manufacture a wide range of antibacterial products like wound dressings, sprays, creams, catheters or surface coatings.

Nanoformula Icon
Unique antibacterial nanoformula
5x Icon
5x more efficient antibacterial effect compared to traditional silver
Drug-resistant Icon
Effective against drug-resistant bacteria
Wound Healing Icon
Supports wound healing
Environmentally Friendly Icon
Environmentally friendly
Multifunctional Icon
Multifunctional: can be used in wound dressings, sprays, on surfaces

As the first product, we developed advanced antibacterial wound dressing. We completed preclinical studies, got the feedback from distributors, medical doctors and end-users and started the CE marking process to receive the marketing approval in EU.

Advanced Antibacterial Wound Dressing
Indications for Nanordica wound dressing:
  • Prophylactic use to avoid infection
  • All types of infected wounds including:
    • Diabetic foot and foot ulcers
    • Burns
    • Surgical wounds
    • Deep traumatic wounds
    • Inflammed wounds
Properties of Nanordica wound dressing:
  • Unique patented composition of nanofibers and antibacterial nanoparticles
  • Inactivates 99.999% drug-resistant bacteria
  • Significantly improves wound healing
  • Does not contain traditional antibiotics
  • Contains 5 times less silver compared to regular silver-based treatments
  • Cost effective and long-lasting
  • Breathable hypoallergenic
  • Available in different sized and with or without adherence
  • Pending CE approval
Development Stage
Stage I — Completed
Research & development, prototypes, IP
Antibacterial nanoformula Lab prototypes Industrial manufacturing In vitro and in vivo testing Provisional patent
Stage II — Ongoing
Clinical evaluation, product-market fit, CE marking
Product-market fit Commerzialication plan Documentation Regulations Pilot clinical study Validated business model Test sales in developing countries
Stage III — Planned
Full IP protection Partnering with pharmaceutical company Commercialization Scale up of sales
KBFI logo Taltech logo ETAG logo Stratuo Incubator logo EAS logo NEMC logo Prototron logo Health Founders logo

Open to collaboration for:
  • Distribution of wound dressings
  • Licensing of underlying antibacterial technology
  • Joint projects to develop new antibacterial devices and solutions according to customer’s needs
Ask for free wound dressing samples
(CE marking pending)
Make a pre-order of wound dressings
Anna Liisa Kubo
Anna-Liisa Kubo, PhD
Product development
10+ years in basic research, R&D and nanotech industry.
Olesja Bondarenko
Olesja Bondarenko, PhD
Strategy and R&D
10+ years of international experience in biosciences and leadership.
Grigory Vasiliev
Grigory Vasiliev, MD
Clinical development
Infectious disease specialist. Practicing MD in leading Estonian hospital.
Taavi Lipstok
Taavi Lipstok
Business development
Go - to- market strategy. Several successful startup exits.

About Nanordica
Nanordica Medical OÜ is a healthtech startup developing advanced antibacterial products. Our competitive edge is our unique technology, a mixture of antibacterial nanoparticles (nanoformula) that was developed as a result of over 10 years of research. Our technology potentiates silver, the „gold standard“ antibacterial agent currently used in medical devices, enabling to achieve superior antibacterial effect. Our first product is antibacterial wound dressing for infected wounds.
Nanordica Medical is a spin-off of the National Institute of Chemical Physics and Biophysics (Estonia).
© 2021 Nanordica Medical OÜ
Register code: 14710113
Billing adress: Vana-Lõuna tn 39a-7, Tallinn, Harjumaa 10134